Eva Hager
16 works · 6,345 citations · h-index 7
Top works
- Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
- Rectal cancer delivery of radiotherapy in adequate time and with adequate dose is influenced by treatment center, treatment schedule, and gender and is prognostic parameter for local control: Results of study CAO/ARO/AIO-94
- IORT with electrons as boost strategy during breast conserving therapy in limited stage breast cancer: Long term results of an ISIORT pooled analysis
- Intraoperative radiation therapy for breast cancer
- IORT with Electrons as Boost Strategy during Breast Conserving Therapy in Limited Stage Breast Cancer: Results of an ISIORT Pooled Analysis
- Toxicity and cosmetic outcome after hypofractionated whole breast irradiation and boost-IOERT in early stage breast cancer (HIOB): First results of a prospective multicenter trial (NCT01343459)
- 312 oral RESULTS OF AN ISIORT POOLED ANALYSIS WITH LINAC-BASED IORT WITH ELECTRONS (IOERT) AS BOOST STRATEGY DURING BREAST CONSERVING THERAPY IN LIMITED STAGE BREAST CANCER
- Hyperthermie in der Onkologie: Eine viel versprechende neue Methode?
- OC-0474: Hypofractionated WBI plus IOERT-boost in early stage breast cancer (HIOB): Updated results of a prospective trial
- OC-0491: Hypofractionated WBI plus IOERT-boost in early stage breast cancer (HIOB): Updated results of a prospective trial
- Glioblastoma multiforme Grad IV: Regionale Tiefenhyperthermie, Antiangiogenese mit Thalidomid, Hochdosis-Ascorbinsäureinfusionen und komplementäre Therapie
- Malignes Melanom Stadium IV: Anwendung von regionaler Tiefenhyperthermie, Tamoxifen, Interferon-α und komplementären Therapien
- P301 Hypofractionated WBI plus IOERT-boost in early stage breast cancer (HIOB): updated results
- SP-0383: Update on HIOB Trial: hypofractionated WBI plus intraoperative boost (IOERT) in early stage breast cancer
- EP-1275 Hypofractionated whole breast irradiation and IOERT in breast cancer: Toxicity and cosmetic outcome
- Verlauf eines myelodysplastischen Syndroms (RAEB II) unter einer komplementären Therapie